These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23559679)

  • 1. Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.
    Tanriover B; Stone PW; Mohan S; Cohen DJ; Gaston RS
    Clin J Am Soc Nephrol; 2013 Jul; 8(7):1258-66. PubMed ID: 23559679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Medicare's coverage of immunosuppression medications for kidney transplant recipients.
    Page TF; Woodward RS
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):435-44. PubMed ID: 19817527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extension of Medicare immunosuppressive drug benefits: a "no brainer" that did not happen.
    Bennett WM
    Clin J Am Soc Nephrol; 2010 May; 5(5):743. PubMed ID: 20448072
    [No Abstract]   [Full Text] [Related]  

  • 4. An (ongoing) shortsighted view on transplant coverage policy.
    Zumoff R
    Nephrol News Issues; 2012 Mar; 26(3):8, 10. PubMed ID: 22479970
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.
    Gharibi Z; Ayvaci MUS; Hahsler M; Giacoma T; Gaston RS; Tanriover B
    Transplantation; 2017 Jun; 101(6):1234-1241. PubMed ID: 27379555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.
    Kadatz M; Gill JS; Gill J; Formica RN; Klarenbach S
    J Am Soc Nephrol; 2020 Jan; 31(1):218-228. PubMed ID: 31704739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonadherence to Immunosuppressive Medications Following Pediatric Kidney Transplantation Within Full Cost Coverage Health System: Prevalence and Correlates.
    Maximo Silva AC; Sanders-Pinheiro H; Leite RF; Joseph MPC; Pestana JOM; Schirmer J; Bartira de Aguiar R
    Exp Clin Transplant; 2020 Oct; 18(5):577-584. PubMed ID: 33143602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug coverage for transplantation turns into political football: big business trumps patients.
    Cohen DJ; Murphy B
    Clin J Am Soc Nephrol; 2010 May; 5(5):746-7. PubMed ID: 20448069
    [No Abstract]   [Full Text] [Related]  

  • 9. Income-related disparities in kidney transplant graft failures are eliminated by Medicare's immunosuppression coverage.
    Woodward RS; Page TF; Soares R; Schnitzler MA; Lentine KL; Brennan DC
    Am J Transplant; 2008 Dec; 8(12):2636-46. PubMed ID: 19032227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The UNOS Renal Transplant Registry: Review of the Last Decade.
    Andre M; Huang E; Everly M; Bunnapradist S
    Clin Transpl; 2014; ():1-12. PubMed ID: 26281122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The financial impact of immunosuppressant expenses on new kidney transplant recipients.
    Gordon EJ; Prohaska TR; Sehgal AR
    Clin Transplant; 2008; 22(6):738-48. PubMed ID: 18673373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing mandated health care reforms: the Affordable Care Act, accountable care organizations, and the Medicare ESRD program.
    Watnick S; Weiner DE; Shaffer R; Inrig J; Moe S; Mehrotra R;
    Clin J Am Soc Nephrol; 2012 Sep; 7(9):1535-43. PubMed ID: 22626961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonadherence to immunosuppressive therapy in kidney transplant recipients: can technology help?
    Nerini E; Bruno F; Citterio F; Schena FP
    J Nephrol; 2016 Oct; 29(5):627-36. PubMed ID: 26885659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical renal transplantation: where are we now, what are our key challenges?
    Chapman JR
    Transplant Proc; 2010 Nov; 42(9 Suppl):S3-6. PubMed ID: 21095448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation.
    Prendergast MB; Gaston RS
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1305-11. PubMed ID: 20448067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of renal transplantation in a Moroccan hospital: results and constraints.
    Haddiya I; Radoui A; Benamar L; Ezaitouni F; Ouzeddoun N; Bayahia R; Rhou H
    Transplant Proc; 2012 Dec; 44(10):2976-81. PubMed ID: 23195009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.
    Lazzaro C; McKechnie T; McKenna M
    J Nephrol; 2002; 15(5):580-8. PubMed ID: 12455727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal Analysis of Market Competition and Density in Renal Transplantation Volume and Outcome.
    Adler JT; Yeh H; Markmann JF; Nguyen LL
    Transplantation; 2016 Mar; 100(3):670-7. PubMed ID: 26574684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C.
    Luan FL; Schaubel DE; Zhang H; Jia X; Pelletier SJ; Port FK; Magee JC; Sung RS
    Transplantation; 2008 Jun; 85(11):1601-6. PubMed ID: 18551066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Transplant and Its Outcomes: Single-Center Experience From India.
    Gupta KL; Pattanashetti N; Ramachandran R; Nada R; Aggarwal R; Sharma A
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):78-82. PubMed ID: 30777528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.